EUVIMEDEUVIMED entdecken
Crossref

Development of New Thiadiazole Derivatives as VEGFR‐2 Inhibitors With Anticancer and Proapoptotic Activities‏

Hazem Elkady iD, Walid E Elgammal, Mohamed M Khalifa iD, Hazem A Mahdy, Ahmed S Ibrahim, Abdullah Y Saad, Bshra A Alsfouk, Eslam B Elkaeed, Ahmed M Metwaly, Ibrahim H Eissa iD

Archiv der Pharmazie · 2025-07 · 358 (7)

DOI: 10.1002/ardp.70042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025-07. Verfasst von Hazem Elkady und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Thiadiazoles, Apoptosis, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: This study was funded by Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2025R142), Princess Nourah bint Abdulrahman U….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of thiadiazole‐based derivatives were synthesized and evaluated for their potential as VEGFR‐2 inhibitors and anticancer agents. Among them, compound 7b demonstrated significant cytotoxic activity against MCF‐7 breast cancer cells, with an IC 50 value of 6.13 µM, surpassing that of the reference drug sorafenib (IC 50 : 7.26 µM). Compound 7b also exhibited potent VEGFR‐2 inhibition with an IC 50 of 40.65 nM, outperforming sorafenib (IC 50 : 53.32 nM). Further investigation into the mechanism of action revealed that compound 7b induced significant changes in the cell‐cycle distribution of MCF‐7 cells, causing G1 arrest and delaying progression through the G2/M phase. Apoptosis analysis demonstrated that compound 7b primarily induced late apoptosis (55.90%) and necrosis (21.81%), with only 22.26% of cells remaining viable. Treatment with 7b increased the expression of the proapoptotic gene BAX (4.19 ± 0.34‐fold) and suppressed the expression of the antiapoptotic gene Bcl‐2 (0.38 ± 0.02‐fold), resulting in a dramatic increase in the BAX/Bcl‐2 ratio (11.03 ± 1.66‐fold). Additionally, caspase‐8 and caspase‐9 levels were elevated by 2.99 ± 0.22‐fold and 4.13 ± 0.11‐fold, respectively, confirming activation of both intrinsic and extrinsic apoptotic pathways. In conclusion, compound 7b is a potent VEGFR‐2 inhibitor with promising anticancer activity, demonstrating cytotoxicity, inhibition of cell migration, and induction of apoptosis in MCF‐7 cells. These results suggest that compound 7b has the potential to be developed as a therapeutic agent for breast cancer treatment, warranting further in vivo and mechanistic studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2ThiadiazolesApoptosisAntineoplastic AgentsProtein Kinase InhibitorsHumansStructure-Activity RelationshipMolecular StructureDrug Screening Assays, AntitumorMCF-7 CellsCell ProliferationDose-Response Relationship, DrugBreast Neoplasms

Stichwörter der Autor:innen

VEGFR‐2apoptosiscaspasesmolecular modelingthiadiazole

Substanzen

Vascular Endothelial Growth Factor Receptor-2ThiadiazolesAntineoplastic AgentsKDR protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
  • Department of Chemistry, Faculty of Science, Al-Azhar University, Nasr City, Cairo, Egypt.
  • Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
  • Department of Pharmaceutical Organic Chemistry, College of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
  • Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia.

ORCID-Profile: Hazem Elkady, Mohamed M Khalifa, Ibrahim H Eissa

Förderung

  • This study was funded by Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2025R142), Princess Nourah bint Abdulrahman U…

Zitieren

APA

Elkady, H., Elgammal, W. E., Khalifa, M. M., Mahdy, H. A., Ibrahim, A. S., Saad, A. Y., Alsfouk, B. A., Elkaeed, E. B., Metwaly, A. M., & Eissa, I. H. (2025). Development of New Thiadiazole Derivatives as VEGFR‐2 Inhibitors With Anticancer and Proapoptotic Activities‏. Archiv der Pharmazie, 358(7). https://doi.org/10.1002/ardp.70042

Vancouver

Elkady H, Elgammal WE, Khalifa MM, Mahdy HA, Ibrahim AS, Saad AY, et al. Development of New Thiadiazole Derivatives as VEGFR‐2 Inhibitors With Anticancer and Proapoptotic Activities‏. Archiv der Pharmazie. 2025;358(7). doi:10.1002/ardp.70042

BibTeX
@article{Elkady2025,
  author = {Elkady, Hazem and Elgammal, Walid E and Khalifa, Mohamed M and Mahdy, Hazem A and Ibrahim, Ahmed S and Saad, Abdullah Y and Alsfouk, Bshra A and Elkaeed, Eslam B and Metwaly, Ahmed M and Eissa, Ibrahim H},
  title = {Development of New Thiadiazole Derivatives as VEGFR‐2 Inhibitors With Anticancer and Proapoptotic Activities‏},
  journal = {Archiv der Pharmazie},
  year = {2025},
  volume = {358},
  number = {7},
  doi = {10.1002/ardp.70042}
}
Kostenlos starten →